Combination antiretroviral therapy (ART) can block multiple stages of the HIV-1 life cycle to
prevent progression to AIDS in people living with HIV-1. However, owing to the persistence …

HIV-1 therapy with single or dual broadly neutralizing antibodies (bNAbs) has shown viral
escape, indicating that at least a triple bNAb therapy may be needed for robust suppression …

Although combination antiretroviral therapy (ART) has reduced mortality and improved
lifespan for people living with HIV, it does not provide a cure. Patients must be on ART for …

HIV broadly neutralizing antibodies (bNAbs) are capable of both blocking viral entry and
driving innate immune responses against HIV-infected cells through their Fc region …

Monoclonal antibodies have been used successfully as recombinant protein therapy;
however, for HIV, multiple broadly neutralizing antibodies may be necessary. We used the …

Both SIV and SHIV are powerful tools for evaluating antibody-mediated prevention and
treatment of HIV-1. However, owing to a lack of rhesus-derived SIV broadly neutralizing …

Broadly neutralizing antibodies (bNAbs) for HIV-1 prevention or cure strategies must inhibit
transmitted/founder and reservoir viruses. Establishing sensitivity of circulating viruses to …

HIV infection requires lifelong antiretroviral therapy (ART) to control disease progression.
Although ART has greatly extended the life expectancy of persons living with HIV (PWH) …

The broadly neutralizing antibody (bNAb) CAP256-VRC26. 25 has exceptional potency
against HIV-1 and has been considered for clinical use. During the characterization and …

The recently published AMP trial (HVTN 703/HPTN 081 and HVTN704/HPTN 085) results
have validated broad neutralising antibodies (bNAbs) as potential anti-HIV-1 agents …